서브메뉴
검색
Mindfulness Meditation as an Adjunct to Esketamine Treatment for Major Depressive Disorder
Mindfulness Meditation as an Adjunct to Esketamine Treatment for Major Depressive Disorder
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202103547
- ISBN
- 9798315731122
- DDC
- 362
- 서명/저자
- Mindfulness Meditation as an Adjunct to Esketamine Treatment for Major Depressive Disorder
- 발행사항
- [Sl] : University of California, Los Angeles, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 67 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 86-11, Section: B.
- 주기사항
- Advisor: Choi, Kristen R.
- 학위논문주기
- Thesis (D.N.P.)--University of California, Los Angeles, 2025.
- 초록/해제
- 요약Background: Major Depressive Disorder (MDD) affects approximately 300 million people worldwide. Despite available treatments, many patients do not achieve full recovery with traditional antidepressants, and others lack access to evidence-based care. Esketamine, a glutamatergic agent approved for treatment-resistant depression, and mindfulness meditation represent promising approaches for depression care that may improve neuroplasticity. The neuroplasticity theory of depression posits that reduced neural plasticity contributes to MDD development, with both esketamine and mindfulness potentially addressing this deficit. Objectives: This quality improvement project aimed to implement and evaluate the feasibility and efficacy of adding mindfulness meditation to esketamine treatments for patients with MDD, with the goal of improving depression outcomes. Methods: A quasi-experimental pilot was conducted at an outpatient psychiatric clinic with 19 participants (10 in mindfulness plus esketamine group, 9 in usual care esketamine-only group). Outcome measures included changes in depressive symptoms using the Patient Health Questionnaire-8 (PHQ-8), mindfulness domains of self-compassion and acting mindfully using Five Facet Mindfulness Questionnaire-Short Form (FFMQ-SF) subscales, and Hope, Agency, and Opportunity (HAO) scores. The intervention consisted of structured mindfulness meditations during esketamine treatments. Data were analyzed using t-tests, regression modeling, and Pearson's r correlations. Results: Patients receiving the mindfulness adjunct had significantly greater PHQ-8 score reductions (4.70 points) compared to the usual care group (1.00 point; p = .014), with a large effect size (Cohen's d = 1.27). Within the mindfulness group, self-compassion scores significantly increased (p .01) and were strongly correlated with PHQ-8 score improvements (r = -0.71, p = .032). Both groups showed excellent treatment adherence. All mindfulness group participants reported satisfaction with the intervention. Conclusion: Adding mindfulness meditations to esketamine treatments provided clinically meaningful improvements in depressive symptoms compared to esketamine alone. The strong correlation between increased self-compassion and depression symptom reduction highlights a potential mechanism for this effect. This feasible, well-received intervention offers a promising approach to enhance outcomes for patients with MDD undergoing esketamine treatment. Future research should examine optimal timing, duration, and long-term benefits of this integrative approach.
- 일반주제명
- Mental health
- 일반주제명
- Nursing
- 일반주제명
- Psychology
- 일반주제명
- Clinical psychology
- 키워드
- Esketamine
- 키워드
- Ketamine
- 키워드
- Meditation
- 키워드
- Mindfulness
- 기타저자
- University of California, Los Angeles Nursing 0597
- 기본자료저록
- Dissertations Abstracts International. 86-11B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017357693
■00520260202103547
■006m o d
■007cr#unu||||||||
■020 ▼a9798315731122
■035 ▼a(MiAaPQ)AAI32041387
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a362
■1001 ▼aTustison, Jennifer.
■24510▼aMindfulness Meditation as an Adjunct to Esketamine Treatment for Major Depressive Disorder
■260 ▼a[Sl]▼bUniversity of California, Los Angeles▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a67 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 86-11, Section: B.
■500 ▼aAdvisor: Choi, Kristen R.
■5021 ▼aThesis (D.N.P.)--University of California, Los Angeles, 2025.
■520 ▼aBackground: Major Depressive Disorder (MDD) affects approximately 300 million people worldwide. Despite available treatments, many patients do not achieve full recovery with traditional antidepressants, and others lack access to evidence-based care. Esketamine, a glutamatergic agent approved for treatment-resistant depression, and mindfulness meditation represent promising approaches for depression care that may improve neuroplasticity. The neuroplasticity theory of depression posits that reduced neural plasticity contributes to MDD development, with both esketamine and mindfulness potentially addressing this deficit. Objectives: This quality improvement project aimed to implement and evaluate the feasibility and efficacy of adding mindfulness meditation to esketamine treatments for patients with MDD, with the goal of improving depression outcomes. Methods: A quasi-experimental pilot was conducted at an outpatient psychiatric clinic with 19 participants (10 in mindfulness plus esketamine group, 9 in usual care esketamine-only group). Outcome measures included changes in depressive symptoms using the Patient Health Questionnaire-8 (PHQ-8), mindfulness domains of self-compassion and acting mindfully using Five Facet Mindfulness Questionnaire-Short Form (FFMQ-SF) subscales, and Hope, Agency, and Opportunity (HAO) scores. The intervention consisted of structured mindfulness meditations during esketamine treatments. Data were analyzed using t-tests, regression modeling, and Pearson's r correlations. Results: Patients receiving the mindfulness adjunct had significantly greater PHQ-8 score reductions (4.70 points) compared to the usual care group (1.00 point; p = .014), with a large effect size (Cohen's d = 1.27). Within the mindfulness group, self-compassion scores significantly increased (p .01) and were strongly correlated with PHQ-8 score improvements (r = -0.71, p = .032). Both groups showed excellent treatment adherence. All mindfulness group participants reported satisfaction with the intervention. Conclusion: Adding mindfulness meditations to esketamine treatments provided clinically meaningful improvements in depressive symptoms compared to esketamine alone. The strong correlation between increased self-compassion and depression symptom reduction highlights a potential mechanism for this effect. This feasible, well-received intervention offers a promising approach to enhance outcomes for patients with MDD undergoing esketamine treatment. Future research should examine optimal timing, duration, and long-term benefits of this integrative approach.
■590 ▼aSchool code: 0031.
■650 4▼aMental health
■650 4▼aNursing
■650 4▼aPsychology
■650 4▼aClinical psychology
■653 ▼aEsketamine
■653 ▼aIntegrative psychiatry
■653 ▼aKetamine
■653 ▼aMeditation
■653 ▼aMindfulness
■690 ▼a0347
■690 ▼a0569
■690 ▼a0621
■690 ▼a0622
■71020▼aUniversity of California, Los Angeles▼bNursing 0597.
■7730 ▼tDissertations Abstracts International▼g86-11B.
■790 ▼a0031
■791 ▼aD.N.P.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17357693▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
